Breaking News Instant updates and real-time market news.

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

16:15
06/17/18
06/17
16:15
06/17/18
16:15

Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA

Cytokinetics announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy, or SMA, were presented at the 2018 Annual Cure SMA Conference in Dallas. This hypothesis-generating study met its primary objective to determine potential pharmacodynamic effects of reldesemtiv after multiple oral doses in patients with SMA, and secondary objectives to evaluate the safety, tolerability and pharmacokinetics of reldesemtiv. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study showed dose- and concentration-dependent increases in time to muscle fatigue as measured by changes from baseline in Six Minute Walk Distance, a sub-maximal exercise test of aerobic capacity and endurance, and Maximal Expiratory Pressure, a measure of strength of respiratory muscles, after eight weeks of treatment with reldesemtiv. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight. The study also showed increases versus placebo in MEP. Adverse events were similar between groups receiving reldesemtiv and placebo. The most commonly observed adverse effects were headache, constipation and nausea. Four patients had serious adverse events reported that resulted in early termination of study drug treatment, all considered to be unrelated to reldesemtiv.

CYTK Cytokinetics
$9.95

0.5 (5.29%)

01/19/18
HCWC
01/19/18
NO CHANGE
Target $20
HCWC
Buy
Cytokinetics price target raised to $20 from $17 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $20 after spending time with management. CK-107 could be the molecule that resets the investment thesis in 2018, Pantginis tells investors in a research note. The analyst looks for a "quick turnaround" in 2018 and keeps a Buy rating on the shares.
11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/17
NEED
11/22/17
DOWNGRADE
Target $12
NEED
Buy
Cytokinetics downgraded to Buy at Needham after failed tirasemtiv Phase 3
As reported earlier, Needham analyst Chad Messer downgraded Cytokinetics to Buy from Strong Buy and cut his price target to $12 from $22 after the company's Phase 3 study of tirasemtiv inamyotrophic lateral sclerosis failed to reach its efficacy endpoints. Messer says the culprit was the high dropout rates due to the tolerability issues of tirasemtiv. The analyst notes that the company will now turn its focus to developing CK-107, which has a superior tolerability profile. Messer adds that the Buy rating still reflects his expectations of potential value creation from CK-107 in FY18.
11/22/17
11/22/17
DOWNGRADE
Target $10

Neutral
Cytokinetics downgraded after tirasemtiv discontinuation at Cantor Fitzgerald
As previously reported, Cantor Fitzgerald analyst Mara Goldstein downgraded Cytokinetics to Neutral from Overweight after the VITALITY-ALS trial failed and the company announced the discontinuation of the tirasemtiv program. While she sees opportunity for upside as clinical data emerge on omecamtiv and CK-2127107, she argues that the time to meaningful data and proximity to year-end makes a Neutral rating appropriate. Goldstein lowered her price target on Cytokinetics to $10 from $21.

TODAY'S FREE FLY STORIES

XLE

Energy Select Sector SPDR

$65.39

-0.17 (-0.26%)

08:19
11/15/18
11/15
08:19
11/15/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIX

Edison International

$53.91

-1.65 (-2.97%)

08:19
11/15/18
11/15
08:19
11/15/18
08:19
Recommendations
Edison International analyst commentary  »

Edison International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$106.97

-0.8 (-0.74%)

08:19
11/15/18
11/15
08:19
11/15/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$53.94

-0.08 (-0.15%)

08:18
11/15/18
11/15
08:18
11/15/18
08:18
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEIX

Consol Energy

$40.57

-0.72 (-1.74%)

08:18
11/15/18
11/15
08:18
11/15/18
08:18
Conference/Events
Consol Energy management to meet with Seaport Global »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

XLU

Utilities SPDR

$54.48

-0.58 (-1.05%)

08:18
11/15/18
11/15
08:18
11/15/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$56.01

-0.34 (-0.60%)

08:18
11/15/18
11/15
08:18
11/15/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BERY

Berry Global

$45.91

-0.49 (-1.06%)

08:18
11/15/18
11/15
08:18
11/15/18
08:18
Hot Stocks
Berry Global sees FY19 adjusted free cash flow $670M »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

XLV

Health Care Select Sector SPDR

$90.31

-0.75 (-0.82%)

08:18
11/15/18
11/15
08:18
11/15/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$20.80

-0.135 (-0.64%)

08:18
11/15/18
11/15
08:18
11/15/18
08:18
Downgrade
KB Home rating change  »

KB Home downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$149.46

-1.05 (-0.70%)

08:17
11/15/18
11/15
08:17
11/15/18
08:17
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$251.14

-2.02 (-0.80%)

08:17
11/15/18
11/15
08:17
11/15/18
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$270.19

-1.81 (-0.67%)

08:17
11/15/18
11/15
08:17
11/15/18
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$26.38

-0.36 (-1.35%)

08:17
11/15/18
11/15
08:17
11/15/18
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMPQ

Umpqua Holdings

$19.06

-0.65 (-3.30%)

08:17
11/15/18
11/15
08:17
11/15/18
08:17
Hot Stocks
Umpqua Holdings appoints Frank Namdar CCO »

Umpqua Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$92.97

0.36 (0.39%)

08:16
11/15/18
11/15
08:16
11/15/18
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

Invesco QQQ Trust

$165.14

-1.34 (-0.80%)

08:16
11/15/18
11/15
08:16
11/15/18
08:16
Technical Analysis
Invesco QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MARK

Remark Holdings

$3.28

-0.23 (-6.55%)

08:16
11/15/18
11/15
08:16
11/15/18
08:16
Recommendations
Remark Holdings analyst commentary  »

Remark Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

$COMP

Nasdaq Composite

$0.00

(0.00%)

08:16
11/15/18
11/15
08:16
11/15/18
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDX

Nasdaq 100 Index

$0.00

(0.00%)

08:16
11/15/18
11/15
08:16
11/15/18
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BERY

Berry Global

$45.91

-0.49 (-1.06%)

08:16
11/15/18
11/15
08:16
11/15/18
08:16
Earnings
Berry Global reports Q4 adjusted EPS 90c, consensus 87c »

Reports Q4 revenue $2.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

08:15
11/15/18
11/15
08:15
11/15/18
08:15
General news
Jobless Claims to be reported at 08:30 »

Week of 11/10 Jobless…

08:15
11/15/18
11/15
08:15
11/15/18
08:15
General news
Empire State Mfg Survey General Business Conditions Index to be reported at 08:30 »

November Empire State Mfg…

08:15
11/15/18
11/15
08:15
11/15/18
08:15
General news
Retail Sales less autos to be reported at 08:30 »

October Retail Sales less…

08:15
11/15/18
11/15
08:15
11/15/18
08:15
General news
Retail Sales to be reported at 08:30 »

October Retail Sales will…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.